Antiinflammatory effect of tepoxalin Blood and synovial tissue studied in patients with knee arthrosis

References

• Aehringhaus U, Wölbing R H, König W, Patrono C, Peskar B M, Peskar B A. Release of leukotriene C4 from human polymorphonuclear leukocytes as determined by radioimmunoassay. FEBS Letters 1982; 146: 111–4
   PubMed Web of Science ®Google Scholar
• Blackwell G J, Flower R J. l-Phenyl-3 pyrazolidone: An inhibitor of arachidonate oxidation in lung and platelets. Br J Pharmacol 1978; 63: 360
   PubMed Web of Science ®Google Scholar
• Borgeat P, Samuelsson B. Arachidonic acid metabolism in polymorphonuclear leukocytes: Effect of ionophore A23187. Proc Natl Acad Sci USA 1979; 76: 2148–52
   PubMed Web of Science ®Google Scholar
• Bray M A. The pharmacology and pathophysiology of leukotriene B4. Brit Med Bull 1983; 39: 249–54
   PubMed Web of Science ®Google Scholar
• Brodie M J, Hensby C N, Parke A, Gordon D. Is prostacyclin the major pro-inflammatory prostanoid in joint fluid?. Life Sci 1980; 27: 603–8
   PubMed Web of Science ®Google Scholar
• Carey F, Forder R A. Radioimmunoassay of LTB4 and 6-trans LTB4: Analytical and pharmacological characterisation of immunoreactive LTB4 in ionophore-stimulated human blood. Prostaglandins Leukot Med 1986; 22: 57–70
   PubMedGoogle Scholar
• Davidson E M, Rae S A, Smith M J H. Leukotriene B4 in synovial fluid. J Pharm Pharmacol 1982; 34: 410
   PubMed Web of Science ®Google Scholar
• Depre M, Van Hecken A, Amout I. Biochemical activity and pharmacokinetics of tepoxalin, a dual inhibitor in healthy volunteers. Proceedings 3rd International Conference on LMHD, Jerusalem, November, 1993, Abstract PI -5
   Google Scholar
• Depre M, Van Hecken A, Verbesselt R, Verpooten G A, Arn-Out J, Brunner F, Jurgens A, Pousset V, Chow A, Baldauf C, Vermylen J, De Broe M, De Schepper P J. Biochemical activity, pharmacokinetics and tolerability of tepoxalin, a cyclooxygenase/5-lipoxygenase inhibitor in man. Int J Clin Pharmacol Res 1996; 16(1)1–8
   PubMedGoogle Scholar
• Dreyling K W, Hoppe U, Peskar B A, Morgenroth K, Kozus-Chek W, Peskar B M. Leukotriene synthesis by human gastrointestinal tissues. Biochim Biophys Acta 1986; 878: 184–93
   PubMed Web of Science ®Google Scholar
• Egg D. Concentrations of prostaglandins D2, E2 F2alpha, 6-keto-Flalpha and thromboxane B2 in synovial fluid from patients with inflammatory joint disorders and osteoarthritis. Z Rheumatol 1984; 43: 89–96
   PubMed Web of Science ®Google Scholar
• Egg D, Giinther R, Herold M, Kerschbaumer F. Prostaglandin E2 und F2alpha. Konzentrationen in der Synovia bei rheumatischen und traumatischen Kniegelenkerkrankun-gen. Z Rheumatol 1980; 39: 170–5
   PubMedGoogle Scholar
• Feuerstein G, Hallenbeck J M. Leukotrienes in health and disease. FASEB 1987; 1: 186–92
   PubMed Web of Science ®Google Scholar
• Ford-Hutchinson A W. Leukotriene B4 in inflammation. Crit Rev Immunol 1990; 10: 1–12
   PubMed Web of Science ®Google Scholar
• Goldyne M E. Leukotrienes: Clinical significance. Journal Am Acad Dermatol 1984; 10: 659
   PubMed Web of Science ®Google Scholar
• Higgs G A, Moncada S. Leukotrienes in disease implication for drug development. Drugs 1985; 30: 1
   PubMed Web of Science ®Google Scholar
• Kazmi S M, Plante R K, Visconti V, Taylor G R, Zhou L, Lau C Y. Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J Cell Bio-chem 1995; 57(2)299–310
   PubMed Web of Science ®Google Scholar
• Kirchner T, Aparicio B, Argentieri D C, Lau C Y, Ritchie D M. Effects of tepoxalin, a dual inhibitor of cyclooxygena-se/5-lipoxygenase, on events associated with NSAID-in-duced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997; 56(6)417–23
   PubMed Web of Science ®Google Scholar
• Klickstein L B, Shapleigh C, Goetzl E J. Lipoxygenation of arachidonic acid as a source of polymorphonuclear leucocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest 1980; 66: 1166–70
   PubMed Web of Science ®Google Scholar
• Kulkami S K, Parale M P. Leukotrienes: Biosynthesis, pharmacology and clinical significance. Drugs of Today 1985; 21: 379
   Google Scholar
• Lewis R A, Austen K F, Soberman R J. Leukotrienes and other products of the 5-lipoxygenase pathway: Biochemistry and relation of pathobiology in human diseases. N Engl J Med 1990; 323: 645
   PubMed Web of Science ®Google Scholar
• Matthews J N S, Airman D G, Campbell M J, Royston P. Analysis of serial measurements in medical research. Br Med J 1990; 300: 230–5
   PubMed Web of Science ®Google Scholar
• Meade E A, Smith W L, DeWitt D L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem 1993; 268: 6610–4
   PubMed Web of Science ®Google Scholar
• Mitchell J A, Akarasereenont P, Thiemermann C, Flower R J, Vane J R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993; 90: 11693–7
   PubMed Web of Science ®Google Scholar
• Morales R E, Johnson B R, Szabo S. Endofhelin induces vascular and mucosal lesions, enhances the injury by HCl/ethanol, and the antibody exerts gastroprotection. FASEB J 1992; 6: 2354
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta M A, Peskar B A. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. ThrombRes 1980; 17: 317–27
   PubMed Web of Science ®Google Scholar
• Peskar B A, Steffens C, Peskar B M. Radioimmunoassay of 6-keto-prostaglandin Flalpha in biological material. Radioimmunoassay of drugs and hormones in cardiovascular medicine, A Albertini, M Daprada, B A Peskar. Elsevier/North Holland Biomedical Press, Amsterdam 1979; 239–50
   Google Scholar
• Ritchie D M, Argentieri D C, Aparicio B L, Plante R K, Lau C Y, Barbone A G. Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. Int J Immunophar-macol 1995; 17(10)805–12
   PubMed Web of Science ®Google Scholar
• Seidemann P, Lohrer F, Graham G G, Duncan M W, Williams K M, Day R O. The stereoselective disposition of enantiomers of ibuprofen in blood, blister and synovial fluid. Br J Clin Pharmac 1994; 38: 221–7
   PubMed Web of Science ®Google Scholar
• Simmet T, Luck W, Delank W K, Peskar B A. Formation of cysteinyl-leukotrienes by human brain tissue. Brain Res 1988; 456: 344–9
   PubMed Web of Science ®Google Scholar
• Stenson W F, Parker C W. Leukotrienes. Adv Clin Med 1984; 30: 175
   Google Scholar
• Szabo S, Goldberg I. Experimental pathogenesis: Drugs and chemical lesions in the gastric mucosa. Scand J Gastroenterol 1979; 25(Suppl 174)
   Google Scholar
• Trang L E, Granström E, Lövgren O. Levels of prostaglandins F2alpha and E2 and thromboxane B2 in joint fluid in rheumatoid arthritis. Scand J Rheumatol 1977; 6: 151–4
   PubMed Web of Science ®Google Scholar
• Verpooten G A, Depre M, Brunner F. 5-lipoxygenase inhibition profile after multiple dose tepoxalin. Proceedings 3rd International Conference on LMHD, Jerusalem, November, 1993, AbstractPl-ll
   Google Scholar
• Walker J R, Boot J R, Cox B, Dawson W. Inhibition of the release of slow-reacting substance of anaphylaxis by inhibitors of lipoxygenase activity. J Pharm Pharmacol 1980; 32: 866–7
   PubMed Web of Science ®Google Scholar
• Wallace J L, Cirino G, Cicala C, Anderson D W, Argentieri D, Capetola R J. Comparison of the ulcerogenic properties of tepoxalin with those of non-steroidal anti-inflammatory drugs (NSAIDs). Agents Actions 1991; 34: 247–50
   PubMedGoogle Scholar
• Wallace J L, McCafferty D M, Carter L, McKnight W, Argentieri D. Tissue selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy?. Gastroenterology 1993; 105: 1630–6
   PubMed Web of Science ®Google Scholar
• Wittenberg H R, Willburger R E, Kleemeyer K S, Peskar B A. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage and bone in degenerative joint diseases. Arthritis Rheum 1993; 36: 1444–50
   PubMed Web of Science ®Google Scholar
• Zhou L, Ritchie D, Wang E Y, Barbone A G, Argentieri D, Lau C Y. Tepoxalin, a novel immunosuppressive agent with different mechanism of action from cyclosporin A. J Immunol 1994; 153(11)5026–37
   PubMed Web of Science ®Google Scholar
• Zhou L, Pope B L, Chourmouzis E, Fung-Leung W P, Lau C Y. Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. Eur J Immunol 1996; 26(1)120–9
   PubMed Web of Science ®Google Scholar